Shamburg News · 8-K filed Oct 21, 2026, 7:31 PM EDT

Eloxx Pharmaceuticals Appoints Geno J. Germano to Board; Announces EXPRESS Phase 2 Trial Design

ELOX · Eloxx Pharmaceuticals, Inc.

  • Leadership change
  • Other event
  • Material agreement
  • Materiality: medium

On October 19, 2026, Eloxx Pharmaceuticals' Board increased its size from five to six directors and appointed Geno J. Germano to fill the new seat, with a term expiring at the 2027 annual meeting. Mr. Germano received an option grant for 13,587 shares of Common Stock at an exercise price of $12.50 per share, vesting over 24 monthly installments. On October 20, 2026, the Company also announced the appointment of T.R. Srinivas, M.D. as Senior Vice President and Chief Medical Officer and the finalized design of its Phase 2 EXPRESS trial of exaluren in nonsense-mutation ADPKD, enrolling about 60 adults for 52 weeks with first patient dosing expected in Q3 2027 and topline data expected in 1H 2029.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 5.02, 8.01, accession 0001193125-26-428116.

Written from the filing by Shamburg Markets. Figures are as reported by the company.